TNF Pharmaceuticals EBITDA Margin 2012-2024 | TNFA

TNF Pharmaceuticals ebitda margin from 2012 to 2024. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

TNF Pharmaceuticals EBITDA Margin 2012-2024 | TNFA

TNF Pharmaceuticals ebitda margin from 2012 to 2024. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$82.4B
Takeda Pharmaceutical (TAK)$44.4B
Astellas Pharma (ALPMY)$21.1B
Sandoz Group AG (SDZNY)$19.8B
United Therapeutics (UTHR)$16.7B
Summit Therapeutics (SMMT)$14B
Shionogi (SGIOY)$12.7B
Neurocrine Biosciences (NBIX)$12.4B
Catalent (CTLT)$10.7B
Madrigal Pharmaceuticals (MDGL)$6.9B
Orion OYJ (ORINY)$6.8B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$5.7B
Corcept Therapeutics (CORT)$5B
Crinetics Pharmaceuticals (CRNX)$4.5B
PTC Therapeutics (PTCT)$3.1B
Dyne Therapeutics (DYN)$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.4B
Soleno Therapeutics (SLNO)$2.2B
Recursion Pharmaceuticals (RXRX)$1.8B
Centessa Pharmaceuticals (CNTA)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B
Ocular Therapeutix (OCUL)$1.6B
Harrow (HROW)$1.6B
NewAmsterdam Pharma (NAMS)$1.6B
Xencor (XNCR)$1.5B
ARS Pharmaceuticals (SPRY)$1.5B
Avadel Pharmaceuticals (AVDL)$1.4B